Skip to content
Study details
Enrolling now

A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis

AstraZeneca
NCT IDNCT07276581ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

320

Study length

about 2.7 years

Ages

18+

Locations

25 sites in AZ, CA, CO +9

About this study

This trial is testing a treatment called AZD1163 for people with rheumatoid arthritis. The goal is to see if this treatment helps improve symptoms and is safe.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Placebo
  • 2.Take AZD1163
PhasePhase 2
Primary goalChange From Baseline in Disease Activity Score-C-Reactive Protein (DAS28-CRP) at Week 12

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low4%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Endpoints

Primary: Change From Baseline in Disease Activity Score-C-Reactive Protein (DAS28-CRP) at Week 12

Secondary: Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 12, Change From Baseline in Simplified Disease Activity Index (SDAI) at Week 12, Summary statistics to evaluate the PK of AZD1163

Body systems

Immune